Tudor Investment Corp ET AL reduced its stake in Xenon Pharmaceuticals Inc. (NASDAQ:XENE - Free Report) by 76.4% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 8,671 shares of the biopharmaceutical company's stock after selling 28,016 shares during the period. Tudor Investment Corp ET AL's holdings in Xenon Pharmaceuticals were worth $340,000 as of its most recent SEC filing.
Several other institutional investors have also recently made changes to their positions in XENE. Quarry LP acquired a new position in Xenon Pharmaceuticals during the 4th quarter worth approximately $78,000. Blue Trust Inc. increased its holdings in shares of Xenon Pharmaceuticals by 140.3% during the fourth quarter. Blue Trust Inc. now owns 2,422 shares of the biopharmaceutical company's stock valued at $95,000 after acquiring an additional 1,414 shares in the last quarter. Avior Wealth Management LLC acquired a new position in shares of Xenon Pharmaceuticals during the fourth quarter worth approximately $101,000. KBC Group NV lifted its holdings in shares of Xenon Pharmaceuticals by 39.8% in the 4th quarter. KBC Group NV now owns 2,742 shares of the biopharmaceutical company's stock worth $107,000 after purchasing an additional 780 shares in the last quarter. Finally, Magnetar Financial LLC bought a new position in shares of Xenon Pharmaceuticals in the 4th quarter worth $210,000. Institutional investors and hedge funds own 95.45% of the company's stock.
Xenon Pharmaceuticals Trading Down 0.5%
Shares of XENE stock traded down $0.16 during trading hours on Thursday, hitting $29.59. 235,584 shares of the company were exchanged, compared to its average volume of 504,554. The firm has a fifty day simple moving average of $34.28 and a 200 day simple moving average of $38.12. Xenon Pharmaceuticals Inc. has a 52-week low of $26.74 and a 52-week high of $46.00. The stock has a market capitalization of $2.27 billion, a price-to-earnings ratio of -10.49 and a beta of 1.21.
Xenon Pharmaceuticals (NASDAQ:XENE - Get Free Report) last posted its earnings results on Monday, May 12th. The biopharmaceutical company reported ($0.83) earnings per share for the quarter, topping the consensus estimate of ($0.90) by $0.07. The business had revenue of $7.50 million during the quarter, compared to analysts' expectations of $1.64 million. During the same quarter in the previous year, the business earned ($0.62) EPS. Sell-side analysts anticipate that Xenon Pharmaceuticals Inc. will post -3.1 EPS for the current year.
Analyst Ratings Changes
Several research analysts have weighed in on the stock. The Goldman Sachs Group lowered their price objective on shares of Xenon Pharmaceuticals from $60.00 to $52.00 and set a "buy" rating on the stock in a report on Thursday, April 17th. William Blair reaffirmed an "outperform" rating on shares of Xenon Pharmaceuticals in a research report on Monday, May 5th. Wells Fargo & Company decreased their price objective on Xenon Pharmaceuticals from $50.00 to $47.00 and set an "overweight" rating for the company in a report on Tuesday. HC Wainwright restated a "buy" rating and issued a $53.00 target price on shares of Xenon Pharmaceuticals in a report on Tuesday. Finally, Royal Bank of Canada decreased their price target on Xenon Pharmaceuticals from $58.00 to $55.00 and set an "outperform" rating for the company in a report on Tuesday. One investment analyst has rated the stock with a hold rating and twelve have given a buy rating to the company. Based on data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average target price of $54.82.
View Our Latest Analysis on XENE
Xenon Pharmaceuticals Company Profile
(
Free Report)
Xenon Pharmaceuticals Inc, a neuroscience-focused biopharmaceutical company, engages in the development of therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN1101, a novel and potent Kv7 potassium channel opener, which is in Phase 3 clinical trials for the treatment of epilepsy and other neurological disorders.
See Also
Before you consider Xenon Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Xenon Pharmaceuticals wasn't on the list.
While Xenon Pharmaceuticals currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
